Abstract 181P
Background
Several targeted therapies are available through reimbursed organ-specific next-generation sequencing (NGS). Agnostic comprehensive genomic profiling (CGP) covering all classes of genomic alterations could improve access to molecularly-guided therapies (MGTs).
Methods
PRECISION is an initiative launched by the Belgian Society of Medical Oncology (ESMO Open. 2022 Aug;7(4):100524). In the prospective GeNeo trial, CGP (FoundationOne CDx or Heme) was centrally done on tumor samples for patients with advanced solid tumors (NCT04641676). In parallel, organ-directed NGS panel testing was mandatory if reimbursed. Patients with no tissue sample were enrolled with a liquid biopsy. Results were discussed at a national molecular tumor board (MTB). Reasons for non-initiation of the recommended treatment were recorded. Clinical and genomic data are stored in the PRECISION database, with prospective follow-up up to 2 years.
Results
From October 2020 to April 2022, 1000 patients were enrolled at 13 sites. CGP results were available for 937 (843 tissue and 94 liquid biopsies) patients, out of which 918 were discussed at the MTB. The largest cohorts were breast (n=137), colorectal (n=128) and rare cancers (n=100). Turnaround-time from sample received to MTB recommendation was ≤ 28 days for 45% of cases and ≤ 37 days for 80%. 576 patients (63%) received at least one recommendation for CGP-based therapy. Cohorts with most treatment recommendations (>75% of cases) were bladder, biliary tract, skin and thyroid cancers. 72% of 469 patients who also had an organ-directed NGS test received at least one additional treatment recommendation based on CGP testing. Among the patients who received at least one MTB recommendation, 123 (21%) were treated accordingly. Reasons for non-compliance include patient ineligibility (26%), physician decision (23%) and treatment unavailability (22%). Follow-up continues.
Conclusions
Tumor-agnostic CGP provides more treatment options to patients with advanced solid tumors when compared to organ-directed NGS panel testing. The national MTB provides recommendations within a clinically relevant timeframe and enhances the uptake of MGTs.
Clinical trial identification
NCT03873103.
Editorial acknowledgement
Legal entity responsible for the study
Belgian Society of Medical Oncology (BSMO).
Funding
Roche, Fondation contre le Cancer, Kom op tegen Kanker.
Disclosure
P.G. Aftimos: Financial Interests, Personal, Advisory Board: Boehringer Ingelheim, Macrogenics, Roche, Novartis, Amcure, Servier, G1 Therapeutics, Radius, Deloitte, Menarini, Gilead, Novartis, Eisai, Lilly; Financial Interests, Personal, Invited Speaker: Synthon, Amgen; Financial Interests, Institutional, Research Grant: Roche. K. Punie: Financial Interests, Institutional, Advisory Board: AstraZeneca, Novartis, Roche, Vifor Pharma, Eli Lilly, Pierre Fabre, McCann Health, Roularta, Teva, Gilead Sciences, Pfizer, Gilead, MSD; Financial Interests, Institutional, Invited Speaker: Pfizer, Roche, Novartis, Eli Lilly, Mundi Pharma, MSD, Medscape, MSD; Financial Interests, Institutional, Other, Consultancy: Roche; Financial Interests, Personal, Other, Consultancy: Gilead, Novartis, MSD, Roche; Financial Interests, Personal, Invited Speaker: Sanofi, AstraZeneca, Exact Sciences, Focus Patient, Pfizer, Gilead Sciences; Financial Interests, Personal, Advisory Board: Seagen, AstraZeneca, Pfizer; Financial Interests, Personal, Ownership Interest: Need Inc.; Financial Interests, Institutional, Funding: Sanofi; Non-Financial Interests, Other, Committee member: ESMO Young Oncologists Committee; Non-Financial Interests, Leadership Role, Vice President: Belgian Society of Medical Oncology BSMO; Non-Financial Interests, Other, Committee Member: ESMO Resilience Task Force; Non-Financial Interests, Leadership Role: EORTC Breast Cancer Task Force Steering Committee Member; Non-Financial Interests, Institutional, Product Samples, Drug provision for academic research: Gilead Sciences; Non-Financial Interests, Advisory Role: Commission personalized medicine Federal Government Belgium; Non-Financial Interests, Advisory Role, External Scientific Advisor: European Medicine Agency. L. Decoster: Financial Interests, Institutional, Advisory Board: AstraZeneca, BMS, MSD; Financial Interests, Institutional, Invited Speaker: BMS, MSD, Roche, Servier, Sanofi; Financial Interests, Institutional, Research Grant, conduct of academic trial: Boehringer Ingelheim; Non-Financial Interests, Leadership Role, member of board: European Cancer Organisation; Non-Financial Interests, Leadership Role, Board member: International Society of Geriatric Oncology (SIOG). C. Van Marcke de Lummen: Financial Interests, Institutional, Advisory Board: Eli Lilly, Novartis, AstraZeneca; Non-Financial Interests, Member of Board of Directors: BSMO. A. Hebrant: Financial Interests, Personal, Full or part-time Employment: Sciensano. G. Raicevic: Financial Interests, Personal, Full or part-time Employment: Sciensano. E. Van Valckenborgh: Financial Interests, Personal, Full or part-time Employment: Sciensano. B. Maes: Financial Interests, Personal, Advisory Board: Servier, AstraZeneca, Illumina; Financial Interests, Personal, Invited Speaker: Pfizer, Illumina; Financial Interests, Institutional, Invited Speaker: Illumina, SeqOne; Non-Financial Interests, Principal Investigator: BSMO. J. Maetens: Financial Interests, Personal, Full or part-time Employment: Sciensano. J.J. Collignon: Financial Interests, Personal, Full or part-time Employment: Sciensano. S. Tejpar: Financial Interests, Institutional, Advisory Board: Roche, Boehringer Ingelheim, Bayer, Daiichi Sankyo; Financial Interests, Personal, Invited Speaker: Amgen, Merck Serono. J. Canon: Financial Interests, Institutional, Research Grant: Roche. S. Rottey: Financial Interests, Institutional, Advisory Board: Pfizer, Merck, Roche, Ipsen, BMS; Financial Interests, Institutional, Invited Speaker: Ipsen, BMS, Astellas; Financial Interests, Institutional, Research Grant: MSD, Roche, BMS; Non-Financial Interests, Principal Investigator, It is my main task in the hospital to attract and perform clinical trials in oncology phase I-III: all companies performing clinical trials in oncology in Europe. All other authors have declared no conflicts of interest.
Resources from the same session
165P - Correlation between trophoblast cell-surface antigen-2 (Trop-2) expression and pathological complete response (pCR) in HER2-positive early breast cancer (EBC): A sub analysis of PHERGain trial
Presenter: Maria Gion Cortes
Session: Poster session 01
166P - Metabolomic prediction of breast cancer treatment toxicities
Presenter: Max Piffoux
Session: Poster session 01
167P - A tumor immune microenvironment-based model for prediction of everolimus efficacy in premenopausal women with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: Preliminary results from MIRACLE trial
Presenter: Tan Yujing
Session: Poster session 01
168P - HUWE1 inhibition has tumor suppressive effect in triple-negative breast cancer cell lines by modulating glycolytic and immune modulatory markers
Presenter: SHRUTI KAHOL
Session: Poster session 01
169P - Integration of metabolomics and transcriptomics to reveal potential biomarkers associated with treatment response of neoadjuvant therapy in HER2+ breast cancer
Presenter: Ningning Zhang
Session: Poster session 01
170P - Clinical significance and functional role of GPR56 (ADGRG1) in breast cancer
Presenter: Haizhu Chen
Session: Poster session 01
172P - T cell-derived circulating DNA and tumour inflammatory microenvironment in EGFR-mutant advanced non-small cell lung cancer: Correlation with the outcome of EGFR TKI treatment
Presenter: Nicha Zungsontiporn
Session: Poster session 01
173P - Expression of programmed death-ligand 1 and EGFR on circulating tumour cells in advanced lung cancer patients
Presenter: Jayant Khandare
Session: Poster session 01
174P - Frequency and prognostic value of circulating tumor cells in cancer of unknown primary
Presenter: Maria Pouyiourou
Session: Poster session 01